Our data revealed that PTEN expression was not altered by ψ-Bufarenogin treatment, which excluded the involvement of PTEN (Supplementary Figure 5C), and a competitive ELISA assay demonstrated that ψ-Bufarenogin significantly repressed the kinase activity of PI3-K in hepatoma cells (Supplementary Figure 5D). The gene discussed is PTEN; the disease is hepatocellular carcinoma.